These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 20799399)
1. [Immunovac-VP4 vaccine used in complex allergen-specific immunotherapy of patients with hay fever]. Poddubikova AM; Kostinov MP Zh Mikrobiol Epidemiol Immunobiol; 2010; (4):44-8. PubMed ID: 20799399 [TBL] [Abstract][Full Text] [Related]
2. Application of bacterial therapeutic vaccine Immunovac-VP4 in the treatment of pollinosis. Kostinov MP; Poddubikova AM; Magarshak OO; Poddubikov AV Ter Arkh; 2018 Apr; 90(3):16-20. PubMed ID: 30701850 [TBL] [Abstract][Full Text] [Related]
3. [Use of therapeutic polycomponent vaccine "Immunovac VP-4" for the treatment of chronic bacterial prostatitis]. Bondarenko VM; Vershinin AE; Kucherskiĭ VM; Mitkov VG; Klimova NE; Kurbatova EA; Egorova NB Zh Mikrobiol Epidemiol Immunobiol; 2004; (3):39-43. PubMed ID: 15346948 [TBL] [Abstract][Full Text] [Related]
4. [An evaluation of the protective activity of a multicomponent vaccine made from opportunistic microorganisms in the oral method of immunization in a model of local staphylococcal infection]. Efremov VN; Poliachenko VM Zh Mikrobiol Epidemiol Immunobiol; 1993; (4):73-6. PubMed ID: 8067121 [TBL] [Abstract][Full Text] [Related]
5. [The protective activity of a multicomponent vaccine made from the antigens of opportunistic microorganisms when administered orally]. Egorova NB; Mansurova NL; Kuz'mina LA; Kaverina KG Zh Mikrobiol Epidemiol Immunobiol; 1993; (1):48-51. PubMed ID: 8067073 [TBL] [Abstract][Full Text] [Related]
6. [The antigen-specific activity of a multicomponent vaccine administered orally and subcutaneously]. Mansurova NL; Chuprinina RP; Egorova NB; Kuz'mina LA; Skorikova IG; Kaverina KG Zh Mikrobiol Epidemiol Immunobiol; 1995; (1):37-9. PubMed ID: 7539974 [TBL] [Abstract][Full Text] [Related]
8. A recombinant Babayeva M; Tabynov K; Nurpeisov T; Fomin G; Renukaradhya GJ; Petrovsky N; Tabynov K Front Immunol; 2022; 13():983621. PubMed ID: 36439113 [TBL] [Abstract][Full Text] [Related]
9. [Naso-subcutaneous application of the polycomponent vaccine VP-4 for the treatment of patients with bronchial asthma and chronic obstructive bronchitis]. Antonova LP; Markova TP; Kurbatova EA Zh Mikrobiol Epidemiol Immunobiol; 2004; (6):36-40. PubMed ID: 15636137 [TBL] [Abstract][Full Text] [Related]
10. [The results of experimental and clinical studies of a multicomponent vaccine made of the antigens from opportunistic microorganisms]. Egorova NB; Efremova VN; Kurbatova EA; Kuz'mina LA Zh Mikrobiol Epidemiol Immunobiol; 1997; (6):96-101. PubMed ID: 9460881 [No Abstract] [Full Text] [Related]
11. [Effect of methods of application of bacterial ligands on activation of lymphoid organs' effectors in mice]. Akhmatova NK; Chertov IV; Akhmatov EA; Kurbatova EA; Egorova NB; Semenova IB Zh Mikrobiol Epidemiol Immunobiol; 2010; (3):56-61. PubMed ID: 20737684 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients. Rossi RE; Monasterolo G Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445 [TBL] [Abstract][Full Text] [Related]
13. Cc-chemokine eotaxin as a marker of efficacy of specific immunotherapy in patients with intermittent IgE-mediated allergic rhinoconjunctivitis. Jahnz-Rózyk K; Targowski T; Głodzinska-Wyszogrodzka E; Płusa T Allergy; 2003 Jul; 58(7):595-601. PubMed ID: 12823117 [TBL] [Abstract][Full Text] [Related]
14. [The specific activity of a multicomponent vaccine made from the antigens of opportunistic microorganisms]. Mansurova NL; Egorova NB; Kaverina KG; Poliachenko VM; Lobova EA Zh Mikrobiol Epidemiol Immunobiol; 1991 Apr; (4):39-41. PubMed ID: 1882605 [TBL] [Abstract][Full Text] [Related]
15. [Concept of inducing of rapid immunological protection against pathogens]. Semenov BF; Zverev VV Zh Mikrobiol Epidemiol Immunobiol; 2007; (4):93-100. PubMed ID: 17882839 [TBL] [Abstract][Full Text] [Related]
16. [The antigenic activity of vaccines made from opportunistic microorganisms in an experiment to immunize animals by oral and combined methods]. Efremova VN; Poliachenko VM; Kaverina KG Zh Mikrobiol Epidemiol Immunobiol; 1992 Feb; (2):40-3. PubMed ID: 1441812 [TBL] [Abstract][Full Text] [Related]
17. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Pajno GB; Vita D; Parmiani S; Caminiti L; La Grutta S; Barberio G Clin Exp Allergy; 2003 Dec; 33(12):1641-7. PubMed ID: 14656349 [TBL] [Abstract][Full Text] [Related]
18. [Protective activity of a cell-free Klebsiella vaccine in infection in mice caused by Streptococcus pneumoniae serotypes]. Kurbatova EA; Egorova NB; Krasnoproshina LI; Rodionychev EA; Mansurova NL Zh Mikrobiol Epidemiol Immunobiol; 1985 Feb; (2):60-5. PubMed ID: 3887815 [TBL] [Abstract][Full Text] [Related]
19. [Multicomponent vaccine VP-4 in the therapy of allergic diseases]. Osipova GL Zh Mikrobiol Epidemiol Immunobiol; 2003; (1):36-42. PubMed ID: 12630351 [TBL] [Abstract][Full Text] [Related]
20. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis. Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]